Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Hospira UK Limited, Horizon, Honey Lane, Hurley, Maidenhead, SL6 6RJ, UK
Methotrexate 2.5 mg/ml Injection.
| Pharmaceutical Form |
|---|
|
Solution for Injection. Vials containing a clear yellow solution. |
Each ml of solution contains 2.5 mg methotrexate (sodium salt formed in situ).
Each vial of 2 ml of solution contains 5 mg methotrexate (sodium salt formed in situ).
For excipients, see 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Methotrexate |
Methotrexate (4-amino-10-methylfolic acid) is a folic acid antagonist which inhibits the reduction of folic acid and increase of tissue cells. Methotrexate enters the cell through an active transport mechanism of reduced folates. As a result of polyglutamation of methotrexate caused by the folylpolyglutamylate enzyme, the duration of the cytotoxic effect of the drug substance in the cell increases. |
| List of Excipients |
|---|
|
Sodium chloride |
5 mg/2 ml: Conventional or Onco-Tain Type I glass vial with rubber stopper, aluminium seal and plastic ‘flip-off’ top. Packs containing 5 vials.
Not all presentations and pack sizes listed above may be marketed.
Hospira UK Limited, Horizon, Honey Lane, Hurley, Maidenhead, SL6 6RJ, UK
PL 04515/0013
21st March 2003
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
